FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2774350147> ?p ?o ?g. }

• W2774350147 endingPage "198" @default.
• W2774350147 startingPage "195" @default.
• W2774350147 abstract "Introduction Patients with gastroenteropancreatic (GEP), metastatic or locally advanced, non-resectable, grade 3 poorly-differentiated neuroendocrine carcinoma (NEC) are treated with cisplatin (or carboplatin)-etoposide in first-line palliative chemotherapy (CT1). However, nearly all patients will develop resistance and there is no standard second-line treatment. Aim PRODIGE 41–BEVANEC is an academic randomized, phase II study designed to evaluate the efficacy of bevacizumab in combination with FOLFIRI after failure of CT1 in unknown primary NEC and GEP-NEC. Materials and methods The main eligibility criteria are age ≥18 years, metastatic (synchronous or metachronous) or locally advanced, non-resectable, grade 3 GEP-NEC, and documented progressive disease during or after CT1 therapy. Results A total of 124 patients will be randomly assigned (1:1) to receive either 5 mg/kg bevacizumab with FOLFIRI, or FOLFIRI alone, every 14 days until disease progression or unacceptable toxicity. The hypothesis is to demonstrate a 6-month overall survival for at least 50% of the patients in bevacizumab arm versus 35% in the control arm (FOLFIRI alone). Secondary endpoints are objective response, response duration, progression-free survival, toxicity, and biochemical response. Conclusion The study is currently opened in France (NCT02820857). The first patient was randomized on September 6, 2017." @default.
• W2774350147 created "2017-12-22" @default.
• W2774350147 creator A5005521442 @default.
• W2774350147 creator A5007381211 @default.
• W2774350147 creator A5007925107 @default.
• W2774350147 creator A5008482986 @default.
• W2774350147 creator A5017132355 @default.
• W2774350147 creator A5025066980 @default.
• W2774350147 creator A5028237042 @default.
• W2774350147 creator A5032193447 @default.
• W2774350147 creator A5039048699 @default.
• W2774350147 creator A5039119608 @default.
• W2774350147 creator A5042575799 @default.
• W2774350147 creator A5049984078 @default.
• W2774350147 creator A5050532099 @default.
• W2774350147 creator A5065620187 @default.
• W2774350147 creator A5069735711 @default.
• W2774350147 creator A5073459177 @default.
• W2774350147 creator A5074346281 @default.
• W2774350147 creator A5076878654 @default.
• W2774350147 creator A5077844357 @default.
• W2774350147 creator A5083252572 @default.
• W2774350147 creator A5083396561 @default.
• W2774350147 creator A5084177861 @default.
• W2774350147 creator A5090375155 @default.
• W2774350147 date "2018-02-01" @default.
• W2774350147 modified "2023-10-17" @default.
• W2774350147 title "Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study" @default.
• W2774350147 cites W1555094309 @default.
• W2774350147 cites W1840972930 @default.
• W2774350147 cites W1973577894 @default.
• W2774350147 cites W1981584797 @default.
• W2774350147 cites W1991773600 @default.
• W2774350147 cites W1995681258 @default.
• W2774350147 cites W2000318498 @default.
• W2774350147 cites W2005348280 @default.
• W2774350147 cites W2024966748 @default.
• W2774350147 cites W2046972992 @default.
• W2774350147 cites W2062776919 @default.
• W2774350147 cites W2063178653 @default.
• W2774350147 cites W2079144528 @default.
• W2774350147 cites W2080769559 @default.
• W2774350147 cites W2081170063 @default.
• W2774350147 cites W2081457024 @default.
• W2774350147 cites W2149214723 @default.
• W2774350147 cites W2161676563 @default.
• W2774350147 cites W2169749676 @default.
• W2774350147 cites W2495028185 @default.
• W2774350147 cites W2612230723 @default.
• W2774350147 doi "https://doi.org/10.1016/j.dld.2017.11.020" @default.
• W2774350147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29258812" @default.
• W2774350147 hasPublicationYear "2018" @default.
• W2774350147 type Work @default.
• W2774350147 sameAs 2774350147 @default.
• W2774350147 citedByCount "17" @default.
• W2774350147 countsByYear W27743501472019 @default.
• W2774350147 countsByYear W27743501472020 @default.
• W2774350147 countsByYear W27743501472021 @default.
• W2774350147 countsByYear W27743501472022 @default.
• W2774350147 countsByYear W27743501472023 @default.
• W2774350147 crossrefType "journal-article" @default.
• W2774350147 hasAuthorship W2774350147A5005521442 @default.
• W2774350147 hasAuthorship W2774350147A5007381211 @default.
• W2774350147 hasAuthorship W2774350147A5007925107 @default.
• W2774350147 hasAuthorship W2774350147A5008482986 @default.
• W2774350147 hasAuthorship W2774350147A5017132355 @default.
• W2774350147 hasAuthorship W2774350147A5025066980 @default.
• W2774350147 hasAuthorship W2774350147A5028237042 @default.
• W2774350147 hasAuthorship W2774350147A5032193447 @default.
• W2774350147 hasAuthorship W2774350147A5039048699 @default.
• W2774350147 hasAuthorship W2774350147A5039119608 @default.
• W2774350147 hasAuthorship W2774350147A5042575799 @default.
• W2774350147 hasAuthorship W2774350147A5049984078 @default.
• W2774350147 hasAuthorship W2774350147A5050532099 @default.
• W2774350147 hasAuthorship W2774350147A5065620187 @default.
• W2774350147 hasAuthorship W2774350147A5069735711 @default.
• W2774350147 hasAuthorship W2774350147A5073459177 @default.
• W2774350147 hasAuthorship W2774350147A5074346281 @default.
• W2774350147 hasAuthorship W2774350147A5076878654 @default.
• W2774350147 hasAuthorship W2774350147A5077844357 @default.
• W2774350147 hasAuthorship W2774350147A5083252572 @default.
• W2774350147 hasAuthorship W2774350147A5083396561 @default.
• W2774350147 hasAuthorship W2774350147A5084177861 @default.
• W2774350147 hasAuthorship W2774350147A5090375155 @default.
• W2774350147 hasConcept C121608353 @default.
• W2774350147 hasConcept C126322002 @default.
• W2774350147 hasConcept C143998085 @default.
• W2774350147 hasConcept C168563851 @default.
• W2774350147 hasConcept C203092338 @default.
• W2774350147 hasConcept C2776694085 @default.
• W2774350147 hasConcept C2776705615 @default.
• W2774350147 hasConcept C2777802072 @default.
• W2774350147 hasConcept C2778119113 @default.
• W2774350147 hasConcept C2778239845 @default.
• W2774350147 hasConcept C2780259306 @default.
• W2774350147 hasConcept C2780739268 @default.
• W2774350147 hasConcept C2781413609 @default.
• W2774350147 hasConcept C2781451048 @default.

• next